Elternwissen kompakt - die kostenlose Vortragsreihe des Familien Forum Brandnertal Brand (ots) - In der ...
Sanofi Announces Upcoming Launch of MyStar Connect®
Vienna, Austria (ots) -
- MyStar Connect® software contributes to Sanofi's commitment in providing integrated diabetes care solutions, and supports healthcare professionals in clinical decision-making - - CE mark for MyStar Connect® -
At the 50th annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria, Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the upcoming launch of MyStar Connect®, an easy-to-use, comprehensive diabetes data management software platform for healthcare professionals (HCPs).
MyStar Connect® will support HCPs in the delivery of individualised patient care by providing necessary insights and analysis to optimise diabetes management. The new software is part of the MyStar® portfolio consisting of medical devices, support services and guidance and connects to Sanofi's BGStar® and MyStar Extra® blood glucose meters.
"At Sanofi, our integrated care strategy, rather than just developing drugs alone, aims to support people with diabetes holistically, improving patient experiences and outcomes," said Pierre Chancel, Senior Vice President, Global Diabetes, Sanofi. "The upcoming launch of MyStar Connect® is another step forward in Sanofi's long term commitment to improve diabetes care, helping to streamline and simplify the way HCPs can access and visualise their patients' blood glucose data."
MyStar Connect® supports clinical decision-making
Research has shown that too much information can cause confusion whereas integrating and simplifying data management has the opposite effect.(1),(2) MyStar Connect® automates data collection from Sanofi's BGStar® and MyStar Extra® blood glucose meters, and safely stores all the patients' data in between visits. MyStar Connect's comprehensive and intuitive dashboard enables HCPs to set personal targets for each patient and quickly review their key metrics, targets and trends. By making use of colour coding to indicate personal target achievements and trend arrows that summarise changes over time, MyStar Connect® helps HCPs to easily identify trends and key areas needing attention and thus supports their clinical decision-making for each individual patient.3
Enhancing patient understanding of health-related data Successful diabetes management requires a high level of patient involvement in self-monitoring and care. With MyStar Connect®, HCPs will be able to help people with diabetes to improve their understanding of the disease and therapy progress by sharing and discussing with them easy-to-read reports.(3)
The CE mark for MyStar Connect® was obtained by Meteda, the developer of the software in partnership with Sanofi.
Now approved in Europe, MyStar Connect® will be available in selected European countries in the beginning of 2015 and will complement the MyStar® portfolio of Sanofi, combining devices, services and guidance for simple and effective diabetes management.
Diabetes is a chronic disease that occurs as type 1 diabetes, which is an autoimmune disease characterised by the lack of insulin (the hormone that regulates blood glucose concentrations) production by the pancreas, and type 2, a metabolic disorder in which there are two main biological defects: a deficient production of insulin and reduced ability of the body to respond to the insulin being produced. Type 1 and type 2 diabetes are characterised by an increase in blood glucose concentrations (hyperglycemia). Over time, uncontrolled hyperglycemia leads to the macrovascular and microvascular complications of diabetes. Macrovascular complications, which affect the large blood vessels, include heart attack, stroke and peripheral vascular disease. Microvascular complications affect the small blood vessels of the eyes (retinopathy), kidney (nephropathy) and nerves (neuropathy). The global incidence of diabetes is growing at an alarming rate, with more than 382 million people worldwide living with the condition today.(4)
About Sanofi Diabetes Sanofi strives to help people manage the complex challenge of diabetes by delivering innovative, integrated and personalized solutions. Driven by valuable insights that come from listening to and engaging with people living with diabetes, the Company is forming partnerships to offer diagnostics, therapies, services, and devices including blood glucose monitoring systems. Sanofi markets both injectable and oral medications for people with type 1 or type 2 diabetes.
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Meteda develops and markets innovative solutions in the field of medicine, telemedicine and lifestyle. In particular, its activity deals with the development of advanced software and hardware to manage diabetes. Meteda's mission is to develop innovative and unique solutions to improve people's lifestyle and healthcare; building on an extensive experience and knowledge in the IT medical sector.
To find out more about the MyStar® portfolio of medical devices, support services and guidance, please visit our MyStar® newsroom: www.newsroom.mystarsanofi.com
References (1.) Rodbard D. Optimizing display, analysis, interpretation and utility of self-monitoring of blood glucose (SMBG) data for management of patients with diabetes. J Diabetes Sci Technol. 2007;1:62-71. (2.) Berner ES, Moss J. Informatics challenges for the impending patient information explosion. J Am Med Inform Assoc 2005; 12:614-7. (3.) Data on file: MyStar Connect Assessment - Internal study. (4.) International Diabetes Federation Facts and Figures http://www.idf.org/worlddiabetesday/toolkit/gp/facts-figures (Accessed: August 14, 2014).
Forward Looking Statements
Sanofi Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward- looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2013. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.